Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurotech International Ltd. ( (AU:NTI) ) has provided an update.
Neurotech International Limited announced the resignation of Dr. Thomas Duthy as an Executive Director, effective immediately, as he pursues other business interests. Dr. Duthy played a crucial role in the company’s clinical and corporate development, including raising $19 million in capital. His departure marks a significant transition for Neurotech as it continues to advance its drug development efforts in pediatric neurological disorders.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company focusing predominantly on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164, and it has completed several significant clinical trials, including Phase II/III trials in Autism Spectrum Disorder (ASD) and Phase I/II trials in PANDAS/PANS and Rett Syndrome. Neurotech is also preparing for a Phase I/II clinical trial in spastic cerebral palsy.
YTD Price Performance: -48.33%
Average Trading Volume: 706,513
Technical Sentiment Signal: Buy
Current Market Cap: A$32.31M
See more data about NTI stock on TipRanks’ Stock Analysis page.